Lbp Am Sa Reduces Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

LBP AM SA lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 8.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,625 shares of the medical equipment provider's stock after selling 5,179 shares during the quarter. LBP AM SA's holdings in Intuitive Surgical were worth $29,035,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of ISRG. Brighton Jones LLC grew its stake in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after buying an additional 731 shares during the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Intuitive Surgical by 0.5% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock worth $99,678,000 after acquiring an additional 883 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Intuitive Surgical by 70.9% in the 4th quarter. Proficio Capital Partners LLC now owns 1,820 shares of the medical equipment provider's stock valued at $950,000 after acquiring an additional 755 shares during the period. NBT Bank N A NY raised its position in Intuitive Surgical by 28.0% in the 4th quarter. NBT Bank N A NY now owns 2,489 shares of the medical equipment provider's stock valued at $1,299,000 after purchasing an additional 544 shares during the last quarter. Finally, Moran Wealth Management LLC grew its position in Intuitive Surgical by 1.7% during the 4th quarter. Moran Wealth Management LLC now owns 1,778 shares of the medical equipment provider's stock worth $928,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of several recent research reports. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. Robert W. Baird decreased their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Truist Financial dropped their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Piper Sandler lowered their price objective on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their price objective for the company from $515.00 to $440.00 in a research note on Monday, June 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $592.59.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $515.91, for a total value of $96,991.08. Following the completion of the sale, the executive vice president owned 5,224 shares of the company's stock, valued at $2,695,113.84. This represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gary Loeb sold 1,700 shares of the business's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $513.18, for a total value of $872,406.00. Following the transaction, the executive vice president owned 2,245 shares in the company, valued at approximately $1,152,089.10. This represents a 43.09% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock worth $2,611,577 in the last quarter. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Down 2.7%

Shares of Intuitive Surgical stock traded down $13.99 during mid-day trading on Friday, hitting $512.06. 2,951,229 shares of the stock were exchanged, compared to its average volume of 1,680,513. The stock has a market capitalization of $183.53 billion, a price-to-earnings ratio of 75.08, a price-to-earnings-growth ratio of 5.60 and a beta of 1.64. The company has a 50-day simple moving average of $538.20 and a 200 day simple moving average of $536.86. Intuitive Surgical, Inc. has a twelve month low of $413.82 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. During the same period in the previous year, the firm earned $1.50 earnings per share. Equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.